NCT01857154

Brief Summary

The purpose of this study is to determine whether consuming calcium carbonate that has been micronized is more effective than the traditional form of calcium carbonate in maintaining or increasing bone mineral density in people who are currently taking bisphosphonates or other bone-health medications.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2013

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

May 8, 2013

Completed
12 days until next milestone

First Posted

Study publicly available on registry

May 20, 2013

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
Last Updated

November 25, 2013

Status Verified

November 1, 2013

Enrollment Period

1.3 years

First QC Date

May 8, 2013

Last Update Submit

November 21, 2013

Conditions

Keywords

Bone mineral densityBone mineral contentBone densityBone healthDual-energy x-ray absorptiometry

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in Bone Mineral Density as a measurement by Dual Energy X-ray Absorptiometry

    Bone density scanning, also called dual-energy x-ray absorptiometry (DXA) or bone densitometry, is an enhanced form of x-ray technology that is used to measure bone mineral density. Imaging with x-rays involves exposing a part of the body to a small dose of ionizing radiation to produce pictures of the inside of the body. Benefits * DXA bone densitometry is a simple, quick and noninvasive procedure. * No anesthesia is required. * The amount of radiation used is extremely small-less than one-tenth the dose of a standard chest x-ray, and less than a day's exposure to natural radiation. * DXA bone density testing is the most accurate method available for the diagnosis of osteoporosis and is also considered an accurate estimate

    0 and 183 days

Secondary Outcomes (5)

  • Blood Chemistry Panel

    0 and 183 days

  • Systolic and Diastolic blood pressure

    0 and 183 days

  • Resting heart rate

    0 and 183 days

  • Self-reported quality of life

    0 and 183 days

  • Number of participants with adverse effects

    up to 183 days

Study Arms (4)

Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3

ACTIVE COMPARATOR

Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3

Dietary Supplement: Micronized Calcium CarbonateDietary Supplement: Vitamin D3

Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3

ACTIVE COMPARATOR

Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.

Dietary Supplement: Non-Micronized Calcium CarbonateDietary Supplement: Vitamin D3

Non-Micronized Calcium Carbonate/Vitamin D3

ACTIVE COMPARATOR

Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.

Dietary Supplement: Non-Micronized Calcium CarbonateDietary Supplement: Vitamin D3

Micronized Calcium Carbonate/Vitamin D3

ACTIVE COMPARATOR

Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3

Dietary Supplement: Micronized Calcium CarbonateDietary Supplement: Vitamin D3

Interventions

Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate. Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.

Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3Micronized Calcium Carbonate/Vitamin D3

Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate. Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate.

Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3Non-Micronized Calcium Carbonate/Vitamin D3
Vitamin D3DIETARY_SUPPLEMENT

All subjects in the study cohort will be administered 800 IU Vitamin D3.

Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3Micronized Calcium Carbonate/Vitamin D3Non-Micronized Calcium Carbonate/Vitamin D3

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Must currently be under the care of a physician and taking prescription medication for bone health
  • Must ensure with medical provider that there are no medical conditions that would preclude participation
  • Must be able to swallow capsules
  • Must be age 21 or above
  • Must agree to follow study requirements as set forth in Informed Consent

You may not qualify if:

  • Men and women not currently taking prescription medication for bone health
  • Conditions that inhibit gastrointestinal absorption of supplements
  • Men and women less than 21 years of age
  • Pregnant or breast feeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Integrative Health Technologies

San Antonio, Texas, 78209, United States

RECRUITING

MeSH Terms

Conditions

Bone Diseases, Metabolic

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

Bone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Gilbert R Kaats, PhD FACN

    Integrative Health Technologies, Inc.

    PRINCIPAL INVESTIGATOR
  • Harry G Preuss, MD MACN

    Georgetown University Medical Center, Dept of Biochemistry, Medicine and Pathology

    STUDY CHAIR
  • Sidney J Stohs, PhD

    Dean Emeritus, Creighton University Health Sciences Center

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Intervention Model
PARALLEL
Sponsor Type
NETWORK
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. Gilbert R. Kaats, PhD

Study Record Dates

First Submitted

May 8, 2013

First Posted

May 20, 2013

Study Start

May 1, 2013

Primary Completion

September 1, 2014

Study Completion

October 1, 2014

Last Updated

November 25, 2013

Record last verified: 2013-11

Locations